The United States Patent and Trademark Office (USPTO) has issued patent number 9,549,899 covering ARYMO™ ER (morphine sulfate) extended-release tablets for oral use only –CII developed using Egalet's proprietary Guardian Technology. It is the second U.S. patent covering ARYMO ER. The patent offers protection through 2033 and is listed in the Orange Book.
European patent number 2393487 has been issued to Egalet and offers protection of products developed using Guardian Technology. Also issued is Australian patent number 2015200243. It is the third in a patent family. Both the European and Australian patents offer protection through 2030.
Canadian patent number 2,751,667 also was issued and covers Guardian Technology's immediate-release system designed to slow the release of the active pharmaceutical ingredient in the presence of alcohol. The patent offers protection through 2030.
"The newly issued patents further strengthen our ability to grow our business through the development of immediate- and extended-release products using our Guardian Technology," said Mark Strobeck, Ph.D., executive vice president and chief operating officer at Egalet.
Egalet has been granted a total of 18 U.S. patents and 95 patents outside of the U.S. that cover Guardian Technology and its product candidates.
